Clinical data | |
---|---|
Other names | EPI-002 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H27ClO5 |
Molar mass | 394.89 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. [1] It is a derivative of bisphenol A [2] and one of the four stereoisomers of EPI-001. [1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer. [3]